The Wilms tumour gene WT1 in leukaemia

Leukemia and Lymphoma

Volumn 27, Issue 3-4, 1997, Pages 207-220

  Pritchard Jones, Kathy ^a   King Underwood, Linda ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Haematopoiesis; Leukaemia; Wilms tumour gene; WT1

Indexed keywords

TRANSCRIPTION FACTOR; ZINC FINGER PROTEIN;

ACUTE LEUKEMIA; APOPTOSIS; CELL CYCLE; DEVELOPMENT; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HEMATOPOIESIS; HUMAN; KIDNEY DEVELOPMENT; LEUKEMIA; LEUKEMOGENESIS; NEPHROBLASTOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0030856906     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709059677     Document Type: Review

References (103)

1. Call, K. M., Glaser, T., Ito, C. Y., Buckler, A. J., Pelletier, J., Haber, D. A., Rose, E. A., Kral, A., Yeger, H., Lewis, W. H., Jones, C. and Housman, D. E. (1990). Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms tumor locus. Cell, 60, 509-520.
2. Bickmore, W. A., Oghene, K., Little, M. H., Seawright, A., van-Heyningen, V. and Hastie, N. D. (1992). Modulation of DNA binding specificity by alternative splicing of the Wilms tumor wt1 gene transcript. Science, 257, 235-237.
3. Phelan, S. A., Lindberg, C. and Call, K. M. (1994). Wilms tumor gene, WT1, mRNA is down-regulated during induction of erythroid and megakaryocytic differentiation of K562 cells. Cell Growth Differ, 5, 677-686.
4. Sekiya, M., Adachi, M., Hinoda, Y., Imai, K. and Yachi, A. (1994). Downregulation of Wilms' tumor gene (wt1) during myelomonocytic differentiation in HL60 cells. Blood. 83, 1876-1882.
5. Kudoh, T., Ishidate, T., Nakamura, T. and Akiyama, T. (1996). Constitutive expression of the Wilms tumor suppressor gene WT1 in F9 embryonal carcinoma cells induces apototic cell death in response to retinoic acid. Oncogene, 13, 1431-1439.
6. Haber, D. A., Sohn, R. L., Buckler, A. J., Pelletier, J., Call, K. M. and Housman, D. E. (1991). Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci U S A, 88, 9618-9622.
7. Brenner, B., Wildhardt, G., Schneider, S. and Royer-Pokora. B. (1992). RNA polymerase chain reaction detects different levels of four alternatively spliced WT1 transcripts in Wilms tumors. Oncogene, 7, 1431-1433.
8. Sharma, P. M., Bowman, M., Madden, S. L., Rauscher, F. J. and Sukumar, S. (1994). RNA editing in the Wilms tumor susceptibility gene, WT1. Genes Dev, 8, 720-731.
9. Bruening, W. and Pelletier, J. (1996). A non-AUG translational initiation event generates novel WT1 isoforms. J-Biol-Chem, 271, 8646-8654.
10. Mundlos, S., Pelletier, J., Darveau, A., Bachmann, M., Winterpacht, A. and Zabel, B. (1993). Nuclear localization of the protein encoded by the Wilms tumor gene WT1 in embryonic and adult tissues. Development, 119, 1329-1341.
11. Telerman, A., Dodemont, H., Degraef, C., Galand, P., Bauwens, S., Van-Oostveldt, P. and Amson, R. B. (1992). Identification of the cellular protein encoded by the human Wilms tumor (WT1) gene. Oncogene, 7, 2545-2548.
12. Menssen, H. D., Renkl, H. J., Rodeck, U., Maurer, J., Notter, M., Schwartz, S., Reinhardt, R. and Thiel, E. (1995). Presence of Wilms tumor gene (WT1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia, 9, 1060-1067.
13. Larsson, S. H., Charlieu, J. P., Miyagawa, K., Engelkamp, D., Rassoulzadegan, M., Ross, A., Cuzin, F., van-Heyningen, V. and Hastie, N. D. (1995). Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell. 81, 391-401.
14. Caricasole, A., Duarte, A., Larsson, S. H., Hastie, N. D., Little, M., Holmes, G., Todorov, I. and Ward, A. (1996). RNA binding by the Wilms tumor suppressor zinc finger proteins. Proc. Natl. Acad. Sci. USA, 93, 7562-7566.
15. Pritchard-Jones, K., Fleming, S., Davidson, D., Bickmore, W., Porteous, D., Gosden, C., Bard, J., Buckler, A., Pelletier, J., Housman, D. et al. (1990). The candidate Wilms tumour gene is involved in genitourinary development. Nature, 346, 194-197.
16. Ton, C. C., Hirvonen, H., Miwa, H., Weil, M. M., Monaghan, P., Jordan, T., van Heyningen, V., Hastie, N. D., Meijers-Heijboer, H., Drechsler, M. et al. (1991). Positional cloning and characterization of a paired box- and homebox-containing gene from the aniridia region. Cell, 67, 1059-1074.
17. Pelletier, J., Bruening, W., Kashtan, C. E., Mauer, S. M., Manivel, J. C., Striegel, J. E., Houghton, D. C., Junien, C., Habib, R., Fouser, L. et al. (1991). Germline mutations in the Wilms tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell, 67, 437-447.
18. Bruening, W., Bardeesy, N., Silverman, B. L., Cohn, R. A., Machin, G. A., Aronson, A. J., Housman, D. and Pelletier, J. (1992). Germline intronic and exonic mutations in the Wilms tumour gene (WT1) affecting urogenital development. Nat Genet, 1, 144-148.
19. Konig, A., Jakubiczka, S., Wieacker, P., Schlosser, H. W. and Gessler, M. (1993). Further evidence that imbalance of WT1 isoforms may be involved in Denys-Drash syndrome. Hum Mol Genet, 2, 1967-1968.
20. Coppes, M. J., Liefers, G. J., Higuchi, M., Zinn, A. B., Balfe, J. W. and Williams, B. R. (1992). Inherited WT1 mutation in Denys-Drash syndrome. Cancer Res, 52, 6125-6128.
21. Pelletier, J., Bruening, W., Li, F. P., Haber, D. A., Glaser, T. and Housman, D. E. (1991). WT1 mutations contribute to abnormal genital system development and hereditary Wilms tumour. Nature, 353, 431-434.
22. Kreidberg, J. A., Sariola, H., Loring, J. M., Maeda, M., Pelletier, J., Housman, D. and Jaenisch, R. (1993). WT-1 is required for early kidney development. Cell, 74, 679-691.
23. Kikuchi, H., Akasaka, Y., Kurosawa, Y., Yoneyama, H., Kato, S. and Hata, J. (1995). A critical mutation in both WT1 alleles is not sufficient to cause Wilms tumor. Febs Lett, 360, 26-28.
24. Sakai, A., Tadokoro, K., Yanagisawa, H., Nagafuchi, S., Hoshikawa, N., Suzuki, T., Kohsaka, T., Hasegawa, T., Nakahori, Y. and Yamada, M. (1993). A novel mutation of the WT1 gene (a tumor suppressor gene for Wilms tumor) in a patient with Denys-Drash syndrome. Hum Mol Genet, 2, 1969-1970.
25. Miwa, H., Beran, M. and Saunders, G. F. (1992). Expression of the Wilms tumor gene (WT1) in human leukemias. Leukemia, 6, 405-409.
26. Miyagi, T., Ahuja, H., Kubota, T., Kubonishi, I., Koeffler, H. P. and Miyoshi, I. (1993). Expression of the candidate Wilms tumor gene, WT1, in human leukemia cells. Leukemia, 7, 970-977.
27. King-Underwood, L., Renshaw, J. and Pritchard-Jones, K. (1996). Mutations in the Wilms Tumor Gene WT1 in Leukemias. Blood, 87, 2171-2179.
28. Inoue, K., Sugiyama, H., Ogawa, H., Nakagawa, M., Yamagami, T., Miwa, H., Kita, K., Hiraoka, A., Masaoka, T., Nasu, K., Kyo, T., Dohy, H., Nakauchi, H., Ishidate, T., Akiyama, T. and Kishimoto, T. (1994). WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood, 84, 3071-3079.
29. Brieger, J., Weidmann, E., Fenchel, K., Mitrou, P. S., Hoelzer, D. and Bergmann, L. (1994). The expression of the Wilms tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia, 8, 2138-2143.
30. Patmasiriwat, P., Fraizer, G. C., Claxton, D., Kantarjian, H. and Saunders, G. F. (1996). Expression pattern of WT1 and GATA-I in AML with chromosome 16q22 abnormalities. Leukemia, 10, 1127-1133.
31. Pritchard-Jones, K., Renshaw, J. and King-Underwood, L. (1994). The Wilms tumour (WT1) gene is mutated in a secondary leukemia in a WAGR patient. Hum Mol Genet, 3, 1633-1637.
32. Fritsch, G., Stimpfl, M., Kurz, M., Printz, D., Buchinger, P., Fischmeister, G., Hoecker, P. and Gadner, H. (1996). The composition of CD34 subpopulations differs between bone marrow, blood and cord blood. Bone-Marrow-Transplant, 17, 169-178.
33. Fraizer, G. C., Patmasiriwat, P., Zhang, X. and Saunders, G. F. (1995). Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow [letter]. Blood, 86, 4704-4706.
34. Hastie, N. D. (1994). The genetics of Wilms tumor-a case of disrupted development. Annu Rev Genet, 28, 523-558.
35. Rodeck, U., Bossier, A., Kari, C., Humphreys, C. W., Gyorfi. T., Maurer, J., Thiel, E. and Menssen, H. D. (1994). Expression of the WT1 Wilms tumor gene by normal and malignant human melanocytes. Int J Cancer, 59, 78-82.
36. Coppes, M. J., Ye, Y., Rackley, R., Zhao, X. L., Liefers, G. J., Casey, G. and Williams, B. R. (1993). Analysis of WT1 in granulosa cell and other sex cord-stromal tumors. Cancer Res. 53, 2712-2714.
37. Bruening, W., Gros, P., Sato, T., Stanimir, J., Nakamura, Y., Housman, D. and Pelletier, J. (1993). Analysis of the 11p13 Wilms tumor suppressor gene (WT1) in ovarian tumors. Cancel Invest, 11, 393-399.
38. Rackley, R., Casey, G., Zhao, X. I., Miller, D. W., Williams. B. R. G. and Coppes, M. J. (1995). Analysis of the Wilms tumor suppressor gene WTI in endometrial carcinoma. Genes Chromosomes and Cancer, 14, 313-315.
39. Quek, H. H., Chow, V. T. and Tock, E. P. (1993). The third zinc finger of the WT1 gene is mutated in Wilms tumour but not in a broad range of other urogenital tumours. Anticancer Res, 13, 1575-1580.
40. Park, S., Schalling, M., Bernard, A., Maheswaran, S., Shipley, G. C., Roberts, D., Fletcher, J., Shipman, R., Rheinwald, J., Demetri, G., Griffin, J., Minden, M., Housman, D. and Haber, D. (1993). The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet, 4, 415-420.
41. Langerak, A. W., Williamson, K. A., Miyagawa, K., Hagemeijer, A., Versnel, M. A. and Hastie, N. D. (1995). Expression of the Wilms tumor gene WT1 in human malignant mesothelioma cell lines and relationship to platelet-derived growth factor A and insulin-like growth factor 2 expression. Genes Chromosom Cancer, 12, 87-96.
42. Brown, K. W., Wilmore, H. P., Watson, J. E., Mott, M. G., Berry, P. J. and Maitland, N. J. (1993). Low frequency of mutations in the WT1 coding region in Wilms tumor. Genes Chromosom Cancer, 8, 74-79.
43. Gessler, M., Konig, A., Arden, K., Grundy, P., Orkin, S., Sallan, S., Peters, C., Ruyle, S., Mandell, J., Li, F., Cavenee, W. and Bruns, G. (1994). Infrequent mutation of the WT1 gene in 77 Wilms Tumors. Hum Mutat, 3, 212-222.
44. Algar, E., Blackburn, D., Kromykh, T., Taylor, G. and Smith, P. (1997). Leukemia, 11, 110-113.
45. Rupprecht, H. D., Drummond, I. A., Madden, S. L., Rauscher, F. J. and Sukhatme, V. P. (1994). The Wilms tumor suppressor gene WT1 is negatively autoregulated. J Biol Chem, 269, 6198-5206.
46. Malik, K. T., Poirier, V., Ivins, S. M. and Brown, K. W. (1994). Autoregulation of the human WT1 gene promoter, Febs Lett, 349, 75-78.
47. Hunger, S. P., Sklar, J. and Link, M. P. (1992). Acute lymphoblastic leukemia occurring as a second malignant neoplasm in childhood: report of three cases and review of the literature. J Clin Oncol, 10, 156-163.
48. Moss, T. J., Strauss, L. C., Das, L. and Feig, S. A. (1989). Secondary leukemia following successful treatment of Wilms tumor. Am J Pediatr Hematol Oncol, 11, 158-161.
49. Perilongo, G., Felix, C. A., Meadows, A. T., Nowell, P., Biegel, J. and Lange, B. J. (1993). Sequential development of Wilms tumor, T-cell acute lymphoblastic leukemia, medulloblastoma and myeloid leukemia in a child with type 1 neurofibromatosis: A clinical and cytogenetic case report. Leukemia, 7, 912-915.
50. Hartley, A. L., Birch, J. M., Harris, M., Blair, V., Morris-Jones, P. H., Gattamaneni, H. R. and Kelsey, A. M. (1994). Leukemia, lymphoma, and related disorders in families of children diagnosed with Wilms tumor. Cancer Genet Cytogenet, 77, 129-133.
51. Orkin, S. H. (1995). Transcription factors and hematopoietic development. J-Biol-Chem, 270, 4955-4958.
52. Haber, D. A., Park, S., Maheswaran, S., Englert, C., Re, G. G., Hazen-Martin, D. J., Sens, D. A. and Garvin, A. J. (1993). WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science, 262, 2057-2059.
53. Luo, X. N., Reddy, J. C., Yeyati, P. L., Idris, A. H., Hosono, S., Haber, D. A., Licht, J. D. and Atweh, G. F. (1995). The tumor suppressor gene WT1 inhibits ras-mediated transformation. Oncagene, 11, 743-750.
54. Haber, D. A., Buckler, A. J., Glaser, T., Call. K. M., Pelletier, J., Sohn, R. L., Douglass, E. C. and Housman, D. E. (1990). An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms tumor. Cell, 61, 1257-1269.
55. Haber, D. A., Timmers, H. T., Pelletier, J., Sharp, P. A. and Housman, D. E. (1992). A dominant mutation in the Wilms tumor gene WT1 cooperates with the viral oncogene EIA in transformation of primary kidney cells. Proc Natl Acad Sci U S A, 89, 6010-6014.
56. Reddy, J. C., Morris, J. C., Wang, J., English, M. A., Haber, D. A., Shi, Y. and Licht, J. D. (1995). WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins. J Biol Chem, 270, 10878-10884.
57. Maheswaran, S., Park, S., Bernard, A., Morris, J. F., Rauscher, F. J., Hill, D. E. and Haber, D. A. (1993). Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci U S A, 90, 5100-5104.
58. Maheswaran, S., Englert, C., Bennett, P., Heinrich, G. and Haber, D. A. (1995). The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes-Der, 9, 2143-2156.
59. Little, M., Holmes, G., Bickmore, W., van Heyningen, V., Hastie, N. and Wainwright, B. (1995). DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome point mutations. Hum Mol Genet, 4, 351-358.
60. Little, M. H., Williamson, K. A., Mannens, M., Kelsey, A., Gosden, C., Hastie, N. D. and van-Heyningen, V. (1993). Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion. Hum Mol Genet,2, 259-264.
61. Schneider, S., Wildhardt, G., Ludwig, R. and Royer-Pokora, B. (1993). Exon skipping due to a mutation in a donor splice site in the WT-1 gene is associated with Wilms tumor and severe genital malformations. Hum Genet, 91, 599-604.
62. Baird, P. N., Santos, A., Groves, N., Jadresic, L. and Cowell, J. K. (1992). Constitutional mutations in the WT1 gene in patients with Denys-Drash syndrome. Hum Mol Genet, 1, 301-305.
63. Wang, Z. Y., Qiu, Q. Q., Gurrieri, M., Huang, J. and Deuel, T. F. (1995). WT1, the Wilms tumor suppressor gene product, represses transcription through an interactive nuclear protein. Oncogene, 10, 1243-1247.
64. Moffett, P., Bruening, W., Nakagama, H., Bardeesy, N., Housman, D., Housman, D. E. and Pelletier, J. (1995). Antagonism of WTI activity by protein self-association. Proc Natl Acad Sci U S A, 92, 11105-11109.
65. Varanasi, R., Bardeesy, N., Ghahremani, M., Petruzzi, M. J., Nowak, N., Adam, M. A., Grundy, P., Shows, T. B. and Pelletier, J. (1994). Fine structure analysis of the WT1 gene in sporadic Wilms tumors. Proc Natl Acad Sci U S A, 91, 3554-3558.
66. Little, M. H., Prosser, J., Condie, A., Smith, P. J., Van-Heyningen, V. and Hastie, N. D. (1992). Zinc finger point mutations within the WT1 gene in Wilms tumor patients. Proc Natl Acad Sci USA, 89, 4791-4795.
67. Simms, L. A., Algar, E. M. and Smith, P. J. (1995). Splicing of exon 5 in the WT1 gene is disrupted in Wilms tumour. Eur-J-Cancer, 31A, 2270-2276.
68. Pritchard-Jones, K. (1995). Mutations in the Wilms tumour gene WT1: what do they mean? Eur J Cancer, 31A, 2138-2140.
69. Englert, C., Vidal, M., Maheswaran, S., Ge, Y., Ezzell, R. M., Isselbacher, K. J. and Haber, D. A. (1995). Truncated WT1 mutants alter the subnuclear localization of the wild-type protein. Proc Natl Acad Sci U S A, 92, 11960-11964.
70. Valcarcel, J., Singh, R., Zamore, P. D. and Green, M. R. (1993). The protein Sex-lethal antagonizes the splicing factor U2AF to regulate alternative splicing of transformer pre-mRNA. Nature, 362, 171-175.
71. Sakamoto, H., Inoue, K., Higuchi, I., Ono, Y. and Shimura, Y. (1992). Control of Drosophila Sex-lethal pre-mRNA splicing by its own female-specific product. Nucleic Acids Res, 20, 5533-5540.
72. Drummond, I. A., Madden, S. L., Rohwer-Nutter, P., Bell, G. I., Sukhatme, V. P. and Rauscher, F. J. (1992). Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science, 257, 674-678.
73. Harrington, M. A., Komcek, B., Song, A., Xia, X. L., Fredericks, W. J. and Rauscher, F. J. (1993). Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms tumor locus. J Biol Chem, 268, 21271-21275.
74. Wang, Z. Y., Madden, S. L., Deuel, T. F. and Rauscher, F. J. (1992). The Wilms tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene. J Biol Chem, 267, 21999-20002.
75. Werner, H., Re, G. G., Drummond, I. A., Sukhatme, V. P., Rauscher, F. J., Sens, D. A., Garvin, A. J., LeRoith, D. and Roberts, C., Jr. (1993). Increased expression of the insulin-like growth factor I receptor gene, IGFIR, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci U S A, 90, 5828-5832.
76. Ryan, G., Steele-Perkins, V., Morris, J. F., Rauscher, F. J. and Dressier, G. R. (1995). Repression of Pax-2 by WT1 during normal kidney development. Development, 121, 867-875.
77. Goodyer, P., Dehbi, M., Torban, E., Bruening, W. and Pelletier, J. (1995). Repression of the retinoic acid receptor-alpha gene by the Wilms tumor suppressor gene product. WT1. Oncogene, 10, 1125-1129.
78. Hewitt, S. M., Hamada, S., McDonnell, T. J., Rauscher, F. J. and Saunders, G. F. (1995). Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms tumor suppressor gene WT1. Cancer-Res, 55, 5386-5389.
79. Englert, C., Hou, X., Maheswaran, S., Bennett, P., Ngwu, C., Re, G. G., Garvin, A. J., Rosner, M. R. and Haber, D. A. (1995). WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO-J, 14, 4662-4675.
80. Reddy, J. C., Hosono, S. and Licht, J. D. (1995). The transcriptional effect of WT1 is modulated by choice of expression vector. J-Biol-Chem, 270, 29976-29982.
81. Reddy, J. C. and Licht, J. D. (1996). The WT1 Wilms tumor suppressor gene: how much do we really know? Biochim-Biophys-Acta, 1287, 1-28.
82. Wang, Z. Y., Qiu, Q. Q., Huang, J., Gurrieri, M. and Deuel, T. F. (1995). Products of alternatively spliced transcripts of the Wilms tumor suppressor gene, WT1, have altered DNA binding specificity and regulate transcription in different ways. Oncogene, 10, 415-422.
83. Nichols, K. E., Re, G. G., Yan. Y. X., Garvin. A. J. and Haber, D. A. (1995). WT1 induces expression of insulin-like growth factor 2 in Wilms tumor cells. Cancer-Res, 55, 4540-4543.
84. Cook, D., Hinkes, M., Bernfield, M. and Rauscher, F. J. (1996). Transcriptional activation of the syndecan-1 promoter by the Wilms tumor protein WT1. Oncogene, 13, 1789-1799.
85. Werner, H., Shen Orr, Z., Rauscher, F. J., Morris, J. F., Roberts, C. T., Jr. and LeRoith, D. (1995). Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol, 15, 3516-3522.
86. Martinerie, C., Chevalier, G., Rauscher, F. J. and Perbal, B. (1996). Regulation of nov by WT1: a potential role for nov in nephrogenesis. Oncogene, 12, 1479-1492.
87. Reiss, K., Porcu, P., Sell, C., Pietrzkowski, Z. and Baserga, R. (1992). The insulin-like growth factor I receptor is required for the proliferation of hemopoietic cells. Oncogene. 7, 2243-2248.
88. Collins, S. J., Robertson, K. A. and Mueller, L. (1990). Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha). Mol-Cell-Biol. 10, 2154-2163.
89. Merino, R., Ding, L., Veis, D. J., Korsmeyer, S. J. and Nunez, G. (1994). Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B-lymphocytes. EMBO-J, 13, 683-691.
90. Bensi, L., Longo, R., Vecchi, A., Messora, C., Garagnani, L., Bernardi, S., Tamassia, M. G. and Sacchi, S. (1995). Bcl-2 oncoprotein expression in acute myeloid leukemia. Haematologia, 80, 98-102.
91. Rackley, R. R., Flenniken, A. M., Kuriyan, N. P., Kessler, P. M., Stoler, M. H. and Williams, B. R. (1993). Expression of the Wilms tumor suppressor gene WTI during mouse embryogenesis. Cell Growth Differ, 4, 1023-1031.
92. Armstrong, J. F., Pritchard-Jones, K., Bickmore, W. A., Hastie, N. D. and Bard, J. B. (1993). The expression of the Wilms tumour gene, WT1, in the developing mammalian embryo. Mech Dev, 40, 85-97.
93. Medvinsky, A. and Dzierzak, E. (1996). Definitive hematopoiesis is autonomously initiated by the AGM region. Cell, 86, 897-906.
94. Fraizer, G. C., Wu, Y. J., Hewitt, S. M., Maity, T., Ton, C. C., Huff, V. and Saunders, G. F. (1994). Transcriptional regulation of the human Wilms tumor gene (WT1). Cell type-specific enhancer and promiscuous promoter J Biol Chem, 269. 8892-8900.
95. Zhang, X., Fraizer, G. and Saunders, G. (1995). Two hematopoietic specific enhancers of the WT1 gene function in different cell lineages. Blood, 86, Abst. no. 2980.
96. Wu, Y., Fraizer, G. C. and Saunders, G. F. (1995). GATA-1 transactivates the WT1 hematopoietic specific enhancer. J Biol Chem. 270. 5944-5949.
97. Renshaw, J., King-Underwood, L. and Pritchard-Jones, K. (1996). Differential splicing of the Wilms tumour (WT1) gene in haemopoietic and genitourinary tissues. Proc. AACR, 37, 529.
98. Hewitt, S. M. and Saunders, G. F. (1996). Differentially spliced exon 5 of the Wilms tumor gene WT1 modifies gene function. Anticancer-Res, 16, 621-626.
99. Kudoh, T., Ishidate, T., Moriyama, M., Toyoshima, K. and Akiyama, T. (1995). G1 phase arrest induced by Wilms tumor protein WT1 is abrogated by cyclin/CDK complexes. Proc Natl Acad Sci U S A, 92, 4517-4521.
100. Yamagami, T., Sugiyama, H., Inoue, K., Ogawa, H., Tatekawa, T., Hirata, M., Kudoh, T., Akiyama, T., Murakami, A. and Maekawa, T. (1996). Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood, 87, 2878-2884.
101. Algar, E. M., Khromykh, T., Smith, S. I., Blackburn, D. M., Bryson, G. J. and Smith, P. J. (1996). A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukemia cell lines. Oncogene, 12, 1005-1014.
102. Lassus, P., Ferlin, M., Piette, J. and Hibner, U. (1996). Anti-apoptotic activity of low levels of wild type p53. EMBO J, 15, 4566-4573.
103. Weinberg, R. A. (1996). E2F and cell proliferation: a world turned upside down. Cell, 85, 457-459.